Trial reportExperimental hematology2013
Reticulocyte-based estimation of red blood cell lifespan.
Trial report in Experimental hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- C282Y Homozygosity Increases Erythrocyte Turnover and Decreases HbA1c-A Population-Based Study.International journal of molecular sciences · 2026Article
- Reticulocytes in donor blood units enhance red blood cell alloimmunization.Haematologica · 2023Article
- Red cell distribution width and erythrocyte osmotic stability in type 2 diabetes mellitus.Journal of cellular and molecular medicine · 2021Article
- Unilateral vocal nerve resection alters neurogenesis in the avian song system in a region-specific manner.PloS one · 2021Article
- Application of Reticulocyte-Based Estimation of Red Blood Cell Lifespan in Anemia Management of End-Stage Renal Disease Patients.The AAPS journal · 2020Observational
- [The life span of red blood cell in patients with severe/very severe aplastic anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
We introduce a new, minimally invasive laboratory technique called reticulocyte-based estimation of lifespan (REBEL) of erythrocytes in humans. Its major advantage over existing techniques is its applicability to patients with both changing and steady-state erythropoiesis status. The feasibility of REBEL was tested in five patients with hemodialysis-dependent end-stage renal disease. The RNA degradation half-life was first determined for each subject on day 1 by flow cytometry measurement of the decay rate of thiazole orange stain. Reticulocyte age distribution was then measured from residual RNA content weekly for 2 months to estimate the RBC production rate time course. Mean RBC lifespan per subject was estimated by fitting the integrated RBC production rate over time to the measured RBC count and optimizing the integration limits. The mean reticulocyte RNA half-life was 0.71 ± 0.11 days. The small coefficient of variation (15.6%) indicated that the degradation rate of RNA did not vary substantially between subjects. The mean RBC lifespan (TRBC = 76.6 ± 23.8 days) was comparable to the reported values for this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.